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ABSTRACT
The aim of the present study was to analyse the diagnostic yield of the rose Bengal test for the rapid
diagnosis of human brucellosis in an emergency department in an area where the disease is endemic.
The study included 711 patients diagnosed initially with brucellosis and 270 controls. Brucellosis
patients were divided into three groups: group I, individuals with no regular exposure to or history of
brucellosis; group II, individuals exposed repeatedly to Brucella infection; and group III, individuals
infected with Brucella who had received appropriate treatment during the previous 12 months. Blood
cultures were positive for 445 (62.6%) brucellosis patients, while the remaining 266 (37.4%) patients
were diagnosed according to clinical and serological criteria. The overall sensitivity of the rose Bengal
test was 92.9%. The speciﬁcities for groups I, II and III were 94.3%, 91.7% and 76.9%, respectively, with
positive likelihood ratios of 16.5, 10.4 and 4.2, respectively. The diagnostic gain after the performance of
the rose Bengal test was good or very good in patients with no previous exposure to Brucella or history of
brucellosis, but poor in patients who were exposed repeatedly to Brucella or had a history of brucellosis
and a low pre-test probability. Use of the rose Bengal test as the sole technique for the diagnosis of
brucellosis in endemic areas should be considered very carefully in the context of patients who are
exposed repeatedly to Brucella or have a history of brucellosis.
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INTRODUCTION
Brucellosis is a worldwide zoonosis with a high
degree of morbidity in humans [1]. The disease
remains endemic in many countries, particularly
around the Mediterranean basin and in the
Middle East, India, Mexico, and Central and
South America, and thereby represents an import-
ant public health problem [2]. In humans, brucel-
losis behaves as a systemic infection with a very
heterogeneous clinical spectrum. The disease
usually presents as fever with no apparent focus,
although there are focal forms in 20–40% of cases
[3]. As the clinical picture of human brucellosis is
fairly non-speciﬁc, a deﬁnitive diagnosis requires
isolation of the causative organism, or the demon-
stration of high levels of speciﬁc antibodies, or
seroconversion.
Febrile syndromes with no apparent focus are a
cause of great concern in patients. They therefore
require a fast and precise aetiological diagnosis.
Results of the evaluation of a dipstick assay for
rapid diagnosis of human Brucella infection have
been reported [4–6], but these indicate that the
sensitivity of the Brucella dipstick assay is lower
than that of the rose Bengal test, a traditional
serological screening test for the diagnosis of
brucellosis.
The rose Bengal plate agglutination test is a
rapid test which was designed originally for
screening use in veterinary medicine, but is now
often used for the diagnosis of human brucellosis
[7–9]. Its high sensitivity, ease and speed of use,
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as well as its low cost, have made it very popular
in hospital emergency departments for the diag-
nosis of febrile syndromes. However, few studies
have evaluated its speciﬁcity with large numbers
of patients with brucellosis, in comparison with
representative controls, in an endemic area.
Therefore, the present study assessed the diag-
nostic yield of the rose Bengal test to deﬁne the
most suitable conditions for its efﬁcient use in
emergency departments in endemic areas.
PATIENTS AND METHODS
Between January 1983 and December 2002, 845 patients with
brucellosis were diagnosed, treated and followed in the
Infectious Diseases Unit of Carlos Haya University Hospital,
a tertiary care centre located in an endemic brucellosis area in
the south of Spain. In order to analyse the sensitivity of the
rose Bengal test, the study was restricted to 711 brucellosis
patients for whom results were available for two or more
blood cultures and a portfolio of serological tests, comprising
rose Bengal and Wright seroagglutination, indirect immuno-
ﬂuorescence, and Coombs or immunocapture agglutination
tests. A control group consisted of 270 individuals: 176 patients
with different infectious, autoimmune or neoplastic processes
with a precise aetiological diagnosis, but which involved an
initial differential diagnosis with brucellosis (group A); 68
asymptomatic individuals who were exposed repeatedly to
Brucella infection during their working day (group B); and 26
asymptomatic patients with a history of brucellosis who had
been treated appropriately and who had shown no evidence of
relapse after 1 year (group C).
A diagnosis of brucellosis was established either by isola-
tion of Brucella spp. from blood culture or other clinical
samples, or the presence of a compatible clinical picture
together with the demonstration of speciﬁc antibodies at
signiﬁcant titres or seroconversion. Signiﬁcant titres were
considered to be a Wright’s seroagglutination titre of ‡ 1 ⁄ 160,
an indirect immunoﬂuorescence titre of ‡ 1 ⁄ 100, and an
immunocapture-agglutination or Coombs anti-brucella test
titre of ‡ 1 ⁄ 320.
For blood cultures, biphasic Ruiz–Castan˜eda medium
(Materiales y Reactivos SA, Madrid, Spain) was used until
1988. After 1988, non-radiometric semi-automated BACTEC
NR 730 or 9240 systems (Becton-Dickinson Diagnostic Instru-
ment Systems, Towson, MD, USA) were used. Blood cultures
were processed according to standard techniques [10], with
incubation for 30 days in biphasic Ruiz–Castan˜eda medium or
the BACTEC NR 730 system, and for 15 days in the BACTEC
9240 system. Blind subcultures were performed on chocolate
agar and Brucella agar (Biomedics, San Sebastian de los Reyes,
Madrid, Spain) after 10, 20 and 30 days, or after 7 and 15 days
when the BACTEC 9240 system was used. These subcultures
were incubated at 37C in a CO2 5–10% v ⁄v atmosphere for
3 days. If growth appeared, the colonies were identiﬁed by
colonial morphology, Gram’s stain, oxidase, catalase and
urease tests, and positive agglutination with speciﬁc anti-
serum. All isolates were sent to the National Brucellosis
Reference Laboratory (Valladolid, Spain) for deﬁnitive identi-
ﬁcation and biotyping.
The rose Bengal plate agglutination test, Wright’s seroag-
glutination, Coombs anti-brucella test and indirect immuno-
ﬂuorescence were performed as described previously [11–13].
The immunocapture-agglutination test (Brucellacapt; Vircell
SL, Santa Fe´, Spain) was performed according to the manu-
facturer’s instructions [14].
For the epidemiological analysis, three patient groups were
deﬁned according to their level of exposure in the cohort of
brucellosis patients: group I, individuals with no regular
exposure to Brucella or history of brucellosis; group II,
individuals exposed repeatedly to Brucella infection; and
group III, individuals infected with brucellosis who had
received appropriate treatment during the previous
12 months. In order to analyse the diagnostic yield of the rose
Bengal test, the sensitivity, speciﬁcity, positive and negative
predictive values, and the positive and negative likelihood
ratios were calculated for the entire cohort of brucellosis
patients, and for groups I, II and III separately.
The different pre-test probabilities of brucellosis in patients
with a febrile syndrome with no apparent focus for > 1 week
was established as described previously [15,16], as well as
from our personal experience. Patients with simply fever with
no apparent focus for > 1 week were assigned a pre-test
probability of 10% (p 0.1); those with fever with no apparent
focus for > 1 week, accompanied by profuse sweating and
arthromyalgias, were assigned a pre-test probability of 20% (p
0.2); and those with fever with no apparent focus for > 1 week,
accompanied by profuse sweating, arthromyalgias and he-
patomegaly, were assigned a pre-test probability of 30% (p
0.3). In accordance with Sackett et al. [17], the pre-test prob-
ability was converted into pre-test odds by dividing the pre-
test probability by 1 ) the pre-test probability. The post-test
odds were calculated by multiplying the pre-test odds by the
positive likelihood ratio. The post-test odds were converted
into post-test probability by dividing the post-test odds by the
post-test odds + 1 [17]. The ﬁnal usefulness or gain of the test
was deﬁned as the difference between the post-test probability
and the pre-test probability. Statistical analysis was performed
with SPSS ⁄PC v. 11.0 software and the two-by-two analyser
v. 1.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The study included 711 brucellosis patients, 487
(68.5%) males and 224 (31.5%) females. The mean
age of the group was 38.2 ± 17.1 years (range,
14–91 years). The mean duration of the symptoms
before diagnosis of brucellosis was 44.0 ±
84.4 days, being < 2 weeks in 239 (33.6%)
patients, between 2 weeks and 1 month in 256
(36%) patients, between 1 and 3 months in 152
(21.4%) patients, and > 3 months in 59 (8.3%)
patients. Fever with no apparent focus was
present in 474 (66.7%) patients, while 237
(33.3%) had focal complications. Table 1 shows
the most relevant clinical data.
In total, 445 (62.6%) patients had positive blood
cultures, while diagnosis of the other 266 (37.4%)
222 Clinical Microbiology and Infection, Volume 11 Number 3, March 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 221–225
patients was based on clinical and serological
criteria. All the bacterial isolates obtained were
identiﬁed as Brucella melitensis. Fourteen of the
patients with brucellosis were excluded from the
ﬁnal analysis, as some epidemiological data were
missing from the charts. Thus, the ﬁnal analysis
included697patientswith brucellosis: 307 in group
I; 339 in group II; and 51 in group III (Table 2).
The overall sensitivity of the rose Bengal test
was 92.9%; this included 93.8% for the patients in
group I, 91.7% for those in group II, and 96.1%
for those in group III (Table 3). The sensitivity
was 89.9% for patients whose symptoms had
lasted for < 2 weeks, 95.7% for those with
symptoms for 2 weeks to 1 month, 94.1% for
those with symptoms for 1–3 months, and 88.1%
for those with symptoms for > 3 months.
Of the 270 patients in the control group, 22
(8.1%) had a positive rose Bengal test result,
including ten (0.6%) of the 176 patients in group
A, six (8.8%) of the 68 patients in group B, and six
(23.1%) of the 26 patients in group C. Therefore,
the speciﬁcity of the test fell markedly from group
I to group III (Table 3).
The positive likelihood ratios of the rose Bengal
test were 16.5, 10.4 and 4.2 for groups I, II and III,
respectively. Combination of the pre-test probab-
ility with its corresponding positive likelihood
ratio showed that the diagnostic usefulness or
gain was good in all patients with suspected
brucellosis who had no regular exposure to or
previous history of the disease, but that it was
inadequate for patients who were exposed repeat-
edly with a low pre-test probability, and for those
patients with a recent history of brucellosis whose
likelihood of having the disease was not high
(Table 4).
DISCUSSION
Despite the important advances made in the
diagnosis of human brucellosis following the
general introduction of new semi-automated
methods for blood culture processing [18], diag-
nosis of this disease is still based mostly on the
demonstration of speciﬁc antibodies by means of
different serological techniques. This is mainly
because the greatest incidence of brucellosis is
found in under-developed countries with poor
technical resources, as well as the fact that it tends
to occur in rural communities.
Table 1. Clinical features of patients with brucellosis
Symptoms and signs No of cases (%)
Fever 702 (98.7)
Chills 606 (85.2)
Sweating 597 (84)
Constitutional symptomsa 533 (75)
Arthralgias 353 (46.6)
Myalgias 292 (41.1)
Hepatomegaly 250 (35.2)
Splenomegaly 148 (20.8)
Focal forms 237 (33.3)
Osteoarticular 142 (20)
Genitourinary 37 (5.2)
Neurological 5 (0.7)
Cardiovascular 7 (1)
Other focal form 28 (3.9)
More than one focal form 18 (2.5)
aTwo or more of the following: anorexia, asthenia and malaise.
Table 2. Results obtained with the rose Bengal test for
different groups of patients with and without brucellosis
Rose Bengal-positive
n (%)
Patients with brucellosis
Group I (n = 307) 288 (93.8)
Group 2 (n = 339) 311 (91.7)
Group 3 (n = 51) 49 (96.1)
Patients without brucellosis
Group A (n = 176) 10 (0.6)
Group B (n = 68) 6 (8.8)
Group C (n = 26) 6 (23.1)
Group I, patients with no history of brucellosis or exposure to Brucella spp.; group
II, patients exposed repeatedly to Brucella; group III, patients with a previous
history of brucellosis; group A, patients with different infectious, autoimmune or
neoplastic diseases; group B, asymptomatic individuals with occupational exposure
to Brucella infection; group C, asymptomatic patients with a history of brucellosis.
Table 3. Diagnostic yield of the rose Bengal test
Sensitivity (%) Speciﬁcity (%) PPV NPV
Patients with no history of or
exposure to Brucella spp.
93.8 94.3 0.97 0.90
Patients exposed repeatedly to
Brucella spp.
91.7 91.2 0.98 0.69
Patients with a previous history
of brucellosis
96.1 76.9 0.89 0.91
PPV, positive predictive value; NPV, negative predictive value.
Table 4. Diagnostic usefulness of the rose Bengal test for
different groups of patients
Brucellosis
patients
Pre-test
probability (%)
Positive
likelihood ratio
Post-test
probability (%)
Group I 10 64
20 16.51 80
30 (95% CI, 9.2–30.1) 87
Group II 10 53
20 10.40 72
30 (95% CI, 5.1–22.3) 81
Group III 10 31
20 4.16 50
30 (95% CI, 2.2–0.17) 64
Group I, patients with no history of brucellosis or exposure to Brucella; group II,
patients exposed repeatedly to Brucella; group III, patients with a previous history
of brucellosis.
95% CI, 95% conﬁdence interval.
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A large number of different tests have been
used for the serological diagnosis of brucellosis,
thus demonstrating the lack of an ideal technique.
Rose Bengal is a rapid plate agglutination test that
uses a suspension of Brucella abortus in an acid
buffer. It is able to detect agglutinating and non-
agglutinating antibodies, and avoids the prozone
phenomenon. This endows the rose Bengal test
with a high degree of sensitivity for diagnosing
infection with Brucella spp., irrespective of the
stage of the disease. This high sensitivity, together
with the fact that the technique is simple and
rapid (c. 4 min), makes the rose Bengal test ideal
for screening patients for human brucellosis.
Although many studies have conﬁrmed the
high sensitivity of the rose Bengal test, informa-
tion about its speciﬁcity in endemic areas is
scarce. In most studies, the information is biased
by the fact that control groups comprised healthy
individuals or patients with other diseases, or
both. Patients who are exposed occupationally to
brucellosis, or who have a recent history of the
disease, have been represented poorly in control
groups.
In a study in an endemic area of Spain, the
speciﬁcity of the rose Bengal test was found to be
only 75% [19]. Studies have shown that oligo-
symptomatic, or even asymptomatic and self-
limiting, episodes of infection are common in
endemic areas [20,21] and that IgG anti-brucella
antibodies can persist for many months after the
conclusion of treatment [22,23]. This accounts for
the high seroprevalence of anti-brucella antibod-
ies in endemic regions [24,25] and in individuals
who are exposed repeatedly [26]. Despite this, the
rose Bengal test is now used in many emergency
departments as a rapid test with which to estab-
lish a diagnosis of brucellosis and initiate therapy.
The results of the present study showed that
the speciﬁcity of the rose Bengal test was 91% in
individuals exposed repeatedly, falling to 76.9%
in patients with a history of brucellosis during the
previous year. The post-test probability and the
diagnostic gain, which were very high in patients
with no history of brucellosis or regular exposure
to Brucella, also fell considerably in patients who
were exposed repeatedly and had a low pre-test
probability, especially for patients with a history
of brucellosis.
Unless accompanied by such characteristic
focal forms as sacroiliitis, orchiepididymitis or
sub-acute lymphocytic meningitis, the symptoms
of brucellosis are non-speciﬁc, and haematologi-
cal and biochemical tests are of little diagnostic
value [2,3]. Establishing a diagnosis of brucellosis,
and prescribing suitable therapy, based on a
positive rose Bengal test in patients who are
exposed repeatedly to or who have a history of
the disease does not therefore seem justiﬁed. To
do so would potentially subject a large number of
individuals to unnecessary treatment for 45 days,
involving potential drug toxicity, as well as
needless additional tests during the following
months. This would not only generate unjustiﬁed
health and social costs, but more importantly, it
might also mask or hide other potentially severe
diseases. The characteristics of the Brucella lipo-
polysaccharide mean that this pathogen has a
very low capacity to cause severe sepsis, shock
and disseminated intravascular coagulation [27],
so that a delay in therapy for a few days does not
affect the prognosis. As the results of serological
tests are generally available within 48 h, there is
no justiﬁcation for not using these serological
techniques in particular patient groups.
A possible bias in the present study might
derive from the method used to assign the values
for the pre-test probability. However, these values
were not assigned at random, but were based on
data from large aetiological studies of fever of
intermediate duration in the south of Spain
[15,16] and from experience in studying the
clinical spectrum of brucellosis for > 20 years [3].
The external validity of these pre-test values
therefore seems clear, at least for countries around
the Mediterranean basin and in the Middle East,
where brucellosis is a frequent cause of febrile
syndrome with no apparent focus.
In conclusion, use of the rose Bengal test as the
sole diagnostic tool to establish treatment of
brucellosis in endemic areas is not a reliable
practice with individuals who are exposed repeat-
edly to the disease and who have a low pre-test
probability, and is even less so with individuals
who have a recent history of brucellosis, irres-
pective of their likelihood of having the disease.
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